Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
A NovoCare® Recognized Care Provider, Weight Watchers' new Med+ program delivers an integrated GLP-1 care model proven to drive greater weight loss results than medication alone A NovoCare® Recogniz
First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.
08:00am, Monday, 05'th Jan 2026
American patients can now receive the first-ever GLP-1 pill for weight loss from Novo Nordisk, marking a new chapter of obesity treatment in the U.S. The cash prices of the drug, called the Wegovy p
Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America
08:00am, Monday, 05'th Jan 2026
Average weight loss of ~17% if all patients stayed on treatment* with Wegovy® (semaglutide) tablets 25 mg (~14% regardless of if patients stayed on treatment**) in the OASIS 4 trial1 Starting dose of
Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category
07:00am, Monday, 05'th Jan 2026
Randomized 6-month data from the REMAIN-1 Midpoint Cohort expected in late January 2026 Topline 6-month data from the REMAIN-1 Pivotal Cohort and potential PMA submission expected in H2 2026 Approxima
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects
07:00am, Monday, 05'th Jan 2026
RHB-102 1 is a proprietary, advanced clinical-stage, once-daily, bimodal extended-release, oral tablet formulation of 5-HT3 antagonist, ondansetron, targeting oncology support, acute gastroenteritis
- The P hase II study for diabetes is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate the efficacy, safety, and tolerability of ASC30 in participants with di
Viking Therapeutics: A Wide-Open Oral GLP-1 Market
02:13am, Thursday, 01'st Jan 2026
Viking Therapeutics is positioned favorably in the oral GLP-1 obesity drug race, with strong Phase 2 results for VK2735. VKTX's oral candidate achieved 12.2% weight loss at the highest dose in 13 week
In the Year of the Weight-Loss Pill, Lilly Still Leads GLP-1s
03:08pm, Wednesday, 31'st Dec 2025
Pill versions of GLP-1 drugs arrive in 2026, but analysts say Eli Lilly's lead in obesity and diabetes treatment should hold for years.
Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4
09:20am, Tuesday, 30'th Dec 2025
Kelowna, British Columbia – December 30, 2025 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, pr
GLP-1 weight-loss pills set to reshape US food demand in 2026
09:21am, Wednesday, 24'th Dec 2025
Analysts predict packaged food manufacturers and fast-food eateries may be pushed to alter more of their goods next year when newly licensed appetite-suppressing GLP-1 tablets become accessible in Jan
US health agency to expand access to GLP-1 weight-loss drugs
04:56pm, Tuesday, 23'rd Dec 2025
The U.S. Centers for Medicare and Medicaid Services said on Tuesday it will negotiate drug pricing with manufacturers of GLP-1 medications to expand access to the drugs that help with weight loss.
Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus
12:06pm, Tuesday, 23'rd Dec 2025
Lexaria Bioscience Corp. (NASDAQ: LEXX) on Tuesday provided an update on its Phase 1b, 12-week chronic study GLP-1-H24-4, recently completed in Australia, focusing on 4 DehydraTECH ( DHT) study arms r
FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
11:16am, Tuesday, 23'rd Dec 2025
CNBC's Annika Kim Constantino reports on the FDA's approval of the first GLP-1 pill for obesity from Wegovy maker Novo Nordisk.
Novo Nordisk Stock Soars on FDA-Cleared GLP-1 Pill
10:38am, Tuesday, 23'rd Dec 2025
Novo Nordisk A/S (NYSE:NVO) stock is up 8.8% to trade at $52.37 at last check, after the biopharmaceutical giant received approval from the U.S. Food & Drug Administration (FDA) for the first ever GLP
Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4
09:29am, Tuesday, 23'rd Dec 2025
DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus® DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus® Recent financings c
